Pilot Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Refractory and Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Interleukin-15 (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 06 Nov 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 11 Jul 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2019 to 17 Jul 2019.
- 25 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 28 Jun 2019 to 1 Jul 2019.